Shots:

• Medexus acquired Aptevo BioTherapeutics for upfront of $30M (inclusive ~$9.5M of working capital acquired) and will pay regulatory milestones on approval of IXINITY in Canada and certain EU countries & commercial milestones if the therapy achieved global sales of $120M by Mar 01- 2035
• The focus of the acquisition is to strengthen Medexus’ specialty product portfolio with the addition of Aptevo’s IXINITY and allow Medexus to leverage its US operations for maximum impact via an expanded US product portfolio
• IXINITY is an IV recombinant factor indicated for patients aged ≥ 12yrs. with Hemophilia B which is a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood. Additionally- the company reports $20M credit facility with MidCap Financial

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: IXINITY